Therapies in Development for KRAS G12C–Mutated NSCLC

Web Exclusives —March 15, 2023


Lung Cancer

The Kirsten rat sarcoma (KRAS) oncogene is the second most frequent lung cancer mutation found in patients with lung cancer. KRAS mutation occurs in 30% of all cases of non–small-cell lung cancer (NSCLC) and has long been considered to be undruggable. KRAS plays a role in molecular switching by converting guanosine triphosphate molecules to guanosine diphosphate molecules, the inactive molecule state. Mutated KRAS protein maintains KRAS in the active state, leading to unregulated oncogene signaling and tumor proliferation. The most common mutation subtype in KRAS-mutated NSCLC is G12C, occurring in 13% of cases in Western countries and 3% to 5% in Asian countries. Recent advances in therapy have given patients with KRAS G12C mutation treatment options with the development of direct KRAS inhibitors. A review published in Cancer Management and Research summarized the targeted therapies and immunotherapy and ongoing clinical trials for patients with NSCLC harboring the G12C mutation.

In May 2021, the FDA granted accelerated approval for sotorasib, a small molecule that irreversibly binds to a small pocket in the KRAS G12C protein, locking it in an inactive state. The approval is for patients with previously treated locally advanced or metastatic NSCLC harboring the KRAS G12C mutation. The CodeBreak 100 phase 1/2 study demonstrated the safety of sotorasib monotherapy along with encouraging antitumor activity in previously treated metastatic NSCLC, whereas the phase 3 CodeBreak 200 study found sotorasib significantly improved progression-free survival compared with docetaxel in patients with previously treated NSCLC harboring the KRAS G12C mutation. In addition, a phase 2 clinical trial found that sotorasib use in patients with previously treated advanced or metastatic KRAS G12C NSCLC resulted in an objective response rate (ORR) of 40.7% and a disease control rate (DCR) of 83.7%. Adagrasib is a KRAS G12C inhibitor under investigation in the KRYSTAL-1 phase 1/2 study. The study demonstrated that adagrasib had favorable safety and efficacy in 116 patients with advanced or metastatic NSCLC harboring KRAS G12C mutations, with 98% of patients having prior treatment. The ORR was 43% and the DCR was 80%. D-1553 is a selective KRAS G12C inhibitor being evaluated in patients with previously treated KRAS G12C–positive NSCLC. The ORR was 40.4% and the DCR was 90.4% in this phase 1 clinical trial.

Immunotherapy clinical trials for treatment of KRAS G12C NSCLC are also underway. Anti–PD-L1 single agents are being investigated in the Checkmate 057 trial (nivolumab versus chemotherapy), the OAK trial (atezolizumab), KEYNOTE-042 trial (pembrolizumab), and IMMUNTRGET study. Anti–PD-L1 combined therapy trials likewise are underway. The KEYNOTE-189 trial is investigating pembrolizumab plus chemotherapy versus chemotherapy alone. The IMPOWER 150 study is evaluating ABCP (atezolizumab, bevacizumab, carboplatin, and paclitaxel), ACP (atezolizumab, carboplatin, and paclitaxel), and BCP (bevacizumab, carboplatin, and paclitaxel) in patients with KRAS G12C mutations and has found the ABCP regimen has better overall survival and progression-free survival when compared with ACP and BCP treatment regimens.

Source: Shu CL, Liu YL. The path to personalized treatment in KRAS-mutant non-small cell lung cancer: a review of targeted therapies and immunotherapy. Cancer Manag Res. 2022;14:3485-3492.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State